Closely monitor & control BP. Sudden stabbing migraine-like headache. Discontinue therapy if anti-erythropoietin, Ab-mediated PRCA is suspected; BP cannot be controlled. Patients w/ epilepsy, history of seizures, or medical conditions associated w/ a predisposition to seizure activity eg, CNS infections & brain metastases; underlying haematologic diseases; porphyria; cancer. Increased incidence of thrombotic vascular events. Closely monitor Hb conc. Platelet count should be regularly monitored during 1st 8 wk of therapy. Other causes of anaemia should be evaluated & treated prior to initiation of therapy & before decision to increase dose. Discontinue if a severe cutaneous reaction eg, Stevens-Johnson syndrome or toxic epidermal necrolysis is suspected. HIV-infected patients. Adult surgery patients in an autologous pre-donation programme & adult perisurgery patients w/o autologous blood donation. Not recommended in perisurgery patients w/ a baseline Hb of >13 g/dL. Chronic liver & renal failure. Pregnancy & lactation.